Revised SPC: Eliquis (apixaban) 2.5 mg film-coated tablets

Section 4.4 relating to patients with active cancer revised with statement that this group can be at high risk of both VTE and bleeding events, and when apixaban is considered for DVT or PE treatment, a careful assessment of the benefits against the risks should be made.

Source:

electronic Medicines compendium